Table 6.

All-causality treatment-emergent adverse events

	Achieved CR		Did not achieve CR
N (%)	Glasdegib + LDAC	LDAC alone	Glasdegib + LDAC	LDAC alone
During the first 90 days	n= 15	n= 1	n= 60	n= 35
AEs	15 (100)	1 (100)	59 (98.3)	35 (100)
Serious AEs	10 (66.7)	0	39 (65.0)	26 (74.3)
Grade 3 or 4 AEs	14 (93.3)	0	49 (81.7)	33 (94.3)
Grade 5 AEs	0	0	12 (20.0)	13 (37.1)
Discontinued due to AEs	1 (6.7)	0	16 (26.7)	12 (34.3)
Glasdegib dose reduced due to AEs	2 (13.3)	N/A	6 (10.0)	N/A
Backbone chemotherapy dose reduced due to AEs	2 (13.3)	0	3 (5.0)	0
Glasdegib temporary discontinuation due to AEs	8 (53.3)	N/A	30 (50.0)	N/A
Backbone chemotherapy temporary discontinuation due to AEs	4 (26.7)	0	16 (26.7)	9 (25.7)
After 90 days	n= 14	n= 1	n= 29	n= 13
AEs	13 (92.9)	1 (100)	23 (79.3)	9 (69.2)
Serious AEs	6 (42.9)	0	16 (55.2)	7 (53.8)
Grade 3 or 4 AEs	10 (71.4)	1 (100)	20 (69.0)	7 (53.8)
Grade 5 AEs	1 (7.1)	0	9 (31.0)	3 (23.1)
Discontinued due to AEs	3 (21.4)	0	8 (27.6)	5 (38.5)
Glasdegib dose reduced due to AEs	4 (28.6)	N/A	1 (3.4)	N/A
Backbone chemotherapy dose reduced due to AEs	4 (28.6)	0	3 (10.3)	0
Glasdegib temporary discontinuation due to AEs	9 (64.3)	N/A	8 (27.6)	N/A
Backbone chemotherapy temporary discontinuation due to AEs	9 (64.3)	1 (100)	6 (20.7)	3 (23.1)

AE adverse event, CR complete remission, LDAC low-dose cytarabine, N/A not applicable